Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Proshares Trust (ZBIO) Cash from Financing Activities (2023 - 2025)

Historic Cash from Financing Activities for Zenas BioPharma (ZBIO) over the last 3 years, with Q3 2025 value amounting to $72.6 million.

  • Zenas BioPharma's Cash from Financing Activities fell 6896.49% to $72.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.3 million, marking a year-over-year decrease of 8144.5%. This contributed to the annual value of $413.0 million for FY2024, which is 195288.33% up from last year.
  • Latest data reveals that Zenas BioPharma reported Cash from Financing Activities of $72.6 million as of Q3 2025, which was down 6896.49% from $1.7 million recorded in Q2 2025.
  • In the past 5 years, Zenas BioPharma's Cash from Financing Activities registered a high of $234.0 million during Q3 2024, and its lowest value of -$614000.0 during Q1 2024.
  • Over the past 3 years, Zenas BioPharma's median Cash from Financing Activities value was $1.8 million (recorded in 2024), while the average stood at $60.9 million.
  • In the last 5 years, Zenas BioPharma's Cash from Financing Activities skyrocketed by 360600.0% in 2024 and then plummeted by 9903.12% in 2025.
  • Over the past 3 years, Zenas BioPharma's Cash from Financing Activities (Quarter) stood at $50000.0 in 2023, then skyrocketed by 3606.0% to $1.9 million in 2024, then soared by 3818.83% to $72.6 million in 2025.
  • Its last three reported values are $72.6 million in Q3 2025, $1.7 million for Q2 2025, and $99000.0 during Q1 2025.